SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No.____1_______)*
Cytoclonal Pharmaceutics Inc.
-----------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value
-------------------------------------------------------------
(Title of Class of Securities)
23282G105
-----------------------------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement [ ].
(A fee is not required only if the filing person: (1) has a previous statement
on file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 7 pages
<PAGE>
CUSIP No. 23282G105 13G Page 2 of 7 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Kinder Investments, L.P.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
New York
- --------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0
BENEFICIALLY --------------------------------------------------------------
OWNED BY 6 SHARED VOTING POWER
EACH 708,000
REPORTING --------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
708,000
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
708,000
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.1%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
CUSIP No. 23282G105 13G Page 3 of 7 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Peyser Associates, LLC
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
New York
- --------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0
BENEFICIALLY --------------------------------------------------------------
OWNED BY 6 SHARED VOTING POWER
EACH 708,000
REPORTING --------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
708,000
- ----------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
708,000
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.1%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
CO.
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
CUSIP No. 23282G105 13G Page 4 of 7 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Brian A. Wasserman
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 708,000
BENEFICIALLY --------------------------------------------------------------
OWNED BY 6 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 708,000
--------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
- ----------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
708,000
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.1%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
Page 5 of 7 pages
Item 1.
(a) Name of Issuer:
Cytoclonal Pharmaceutics Inc.
(b) Address of Issuer's Principal Executive Offices:
9000 Harry Hines Boulevard
Dallas, TX 75232
Item 2.
(a) Name of Person Filing:
Kinder Investments, L.P. ("Kinder Investments"); Peyser
Associates, LLC ("Peyser"), the general partner of Kinder
Investments; and Brian A. Wasserman ("Wasserman"), the managing
member of Peyser (together, the "Reporting Parties"). See
attached Exhibit A which is their agreement to file this Schedule
on behalf of each of them.
(b) Address of Principal Business Office or, if None, Residence:
The Reporting Parties' business address is 1500 Hempstead
Turnpike, East Meadow, New York 11554.
(c) Citizen:
Kinder Investments is a New York partnership, Peyser is a New
York corporation, and Wasserman is a citizen of the United
States.
(d) Title of Class of Securities:
Common Stock, $.01 par value ("shares").
(e) CUSIP#:
23282G105
Item 4. Ownership:
(a)(b) As of December 31, 1997, the Reporting Parties may be deemed to
beneficially own 708,000 shares or 8.1% of the Issuer's shares as
follows: (i) 668,000 shares owned directly by Kinder Investments,
and (ii) warrants to purchase 40,000 shares at an exercise price
of $3.75 per share, expiring November 2, 2000 owned directly by
Kinder Investments.
(c) Wasserman, as the managing member of Peyser, has sole voting and
dispositive control of shares owned by Kinder Investments.
Item 5. Ownership of Five Percent or Less of a Class:
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company:
Not applicable.
<PAGE>
Page 6 of 7 pages
Item 8. Identification and Classification of Members of the Group:
Not applicable.
Item 9. Notice of Dissolution of Group:
Not applicable.
Item 10. Certification:
By signing below we certify that to the best of our knowledge
and belief, the securities referred to above were acquired in
the ordinary course of business and were not acquired for the
purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and
were not acquired in connection with or as participant in any
transaction having such purpose of effect.
SIGNATURES
After reasonable inquiry and to the best knowledge and belief of the
Reporting Persons, each such person or entity certifies that the information set
forth in this statement is true, complete and correct.
Kinder Investments, L.P.
/s/ Brian A. Wasserman
Dated: April 8, 1998 By:________________________________
New York, New York Brian A. Wasserman
Managing Member
Peyser Associates, LLC
Peyser Associates, LLC
/s/ Brian A. Wasserman
Dated: April 8, 1998 By:_________________________________
New York, New York Brian A. Wasserman
Managing Member
/s/ Brian A. Wasserman
Dated: April 8, 1998 _________________________________
Brian A. Wasserman
Page 7 of 7 pages
EXHIBIT A
AGREEMENT
JOINT FILING OF SCHEDULE 13G
The Undersigned hereby agree to jointly prepare and file with regulatory
authorities a Schedule 13G and any future amendments thereto reporting each of
the undersigned's ownership of securities of Cytoclonal Pharmaceutics Inc. and
hereby affirm that such Schedule 13G is being filed on behalf of each of the
undersigned.
Kinder Investments, L.P.
/s/ Brian A. Wasserman
Dated: April 8, 1998 By:________________________________
New York, New York Brian A. Wasserman
Managing Member
Peyser Associates, LLC
Peyser Associates, LLC
/s/ Brian A. Wasserman
Dated: April 8, 1998 By:_________________________________
New York, New York Brian A. Wasserman
Managing Member
/s/ Brian A. Wasserman
Dated: April 8, 1998 _________________________________
Brian A. Wasserman
